NCT07683013
Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria shortened, about 10 words
- Start date changed from estimate of Jul 2026 to Aug 3, 2026
- Secondary endpoints: details revised at 1 of 5 entries
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Recommended Phase 2 Dose (RP2D) Based on Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT)
Timeframe: Up to 12 weeks after the first dose of the combination therapy
Secondary (5)
Change From Baseline in Prostate-Specific Antigen (PSA) Levels
Maximum Observed Plasma Concentration (Cmax and Cmax,ss) of Niclosamide, Metabolite M1, and Enzalutamide
Area Under the Plasma Concentration-Time Curve (AUCt and AUCtau) of Niclosamide, Metabolite M1, and Enzalutamide
Time to Maximum Observed Plasma Concentration (Tmax and Tmax,ss) of Niclosamide, Metabolite M1, and Enzalutamide
Elimination Half-life (t1/2) of Niclosamide, Metabolite M1, and Enzalutamide
Arms and interventions
Enzalutamide + CP-PCA07Experimental
Patients will receive combination therapy with CP-PCA07 and Enzalutamide. Enzalutamide will be administered orally once daily at a fixed dose of 160 mg. CP-PCA07 will be administered orally three times daily, starting at 600 mg/day, with planned dose escalation to 900 mg/day and 1,200 mg/day according to the protocol-specified 3+3 dose-escalation criteria and dose-limiting toxicity evaluation.
Drugs: CP-PCA07, Enzalutamide 40 mg capsule
Sites
1 site in 1 country
- Seoul National University HospitalSeoul, South Korea